https://doi.org/10.4081/hmr.v1i3.621

The role of FVIII/VWF concentrates in the treatment of von Willebrand diseasel

Vol. 1 No. 3: von Willebrand disease: an update 80 years after its first description
Published: June 16, 2009
Abstract Views: 206
PDF: 1470
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Massimo Morfini
support@pagepress.org
Two are the goals of treatment of bleeding episodes in patients with von Willebrand disease (VWD): to correct the abnormal platelet adhesion due to reduced and/or dysfunctional von Willebrand Factor (VWF) and to increase the low level of Factor VIII (FVIII). Replacement therapy with plasma-derived FVIII/VWF concentrates is required for VWD patients who do not respond to desmopressin. Several factors should be taken into account to design and optimize the replacement therapy of VWD. As for other inherited bleeding disorders, the choice of a specific treatment requires an accurate diagnosis, which is of a particular relevance in VWD because of the heterogeneity of phenotypes.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Morfini, M. (2009). The role of FVIII/VWF concentrates in the treatment of von Willebrand diseasel. Hematology Meeting Reports (formerly Haematologica Reports), 1(3). https://doi.org/10.4081/hmr.v1i3.621
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).